RxDoctor Payments Data

Brian Bracy, MD

Family Medicine · Fayetteville, ARNPI 1770798878

Payments from drug & device makers

$3,581in general payments, 2019–2025

Across 196 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$500
  • AbbVie$417
  • Novo Nordisk$408
  • Lilly USA, LLC$267
  • Astellas Pharma US Inc$247
  • Antares Pharma, Inc.$238
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$3,43596%
  • Education$1464%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,581 in reported general payments places this provider in the 80th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$36,116
Medicare patients
91
Services billed
692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide66$97,585
HumiraAdalimumab11$78,738
OzempicSemaglutide66$69,328
XareltoRivaroxaban18$22,586
UbrelvyUbrogepant15$18,360
EliquisApixaban28$17,672
MyrbetriqMirabegron19$15,553
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog38$15,124
Tresiba Flextouch U-100Insulin Degludec13$13,479
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$9,557
Bydureon BciseExenatide Microspheres12$9,337
VoqueznaVonoprazan Fumarate14$8,909
Nucynta ErTapentadol Hcl13$8,543
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$7,992
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$5,492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira, Ubrelvy, Synthroid$417$98,24942 claims
Lilly USA, LLCMounjaro$267$97,58566 claims
Novo NordiskOzempic$408$69,32866 claims
PfizerEliquis$500$17,67228 claims
Astellas Pharma US IncMyrbetriq$247$15,55319 claims
GSKTrelegy Ellipta$44$9,55711 claims
Phathom Pharmaceuticals, Inc.Voquezna$88$8,90914 claims
AstraZenecaBreztri Aerosphere$49$7,99213 claims
Esperion Therapeutics, Inc.Nexletol$24$5,28413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →